Vac__-Doctoral ; Achilles Msca Doctoral Network

Puesto: VAC_117_2025 -DOCTORAL CANDIDATES (ACHILLES MSCA DOCTORAL NETWORK)
Organisation/Company Josep Carreras Leukaemia Research Institute (IJC) Research Field Medical sciences » Cancer research Researcher Profile First Stage Researcher (R1) Positions PhD Positions Final date to receive applications 28 Feb 2026 - 23:59 (Europe/Madrid) Country Spain Type of Contract Temporary Job Status Full-time Is the job funded through the EU Research Framework Programme? Horizon Europe - MSCA Marie Curie Grant Agreement Number  Is the Job related to staff position within a Research Infrastructure?

Yes

Offer Description
ACHILLES: ADVANCING IN THE CHALLENGE OF IMPROVING LYMPHOMA AND LEUKEMIA SURVIVAL

ACHILLES is a  Marie Skłodowska Curie Action  Doctoral Network (MSCA-DN) funded by the European Commission under the Horizon Europe framework programme.

ACHILLES will train  16 Doctoral Candidates (DCs) across 15 host institutions in 12 European countries , fostering a new generation of leaders in experimental hemato-oncology and providing them with a comprehensive skill set to advance their careers in this vital field.

ACHILLES is supported by experts in hemato-oncology and experimental therapeutics, integrating research on biomarkers and therapeutic targets, mathematical and computational modeling, therapy design, and preclinical and clinical evaluation to advance new treatments.

This dynamic environment will provide ACHILLES DCs with a thorough understanding of the full journey from basic discoveries to the creation of new therapeutic strategies and diagnostic tools that directly benefit patients with leukemia and lymphoma.

HOW TO APPLY

Please complete the application form below to  apply for a maximum of three DC positions  and provide the following information  in English :

* All documents must be submitted in PDF format.

Personal details, including full name, gender, nationality, and contact information.

Curriculum vitae  including contact details of 2 referees.

Motivation letter  (up to 2 pages) describing your research experience, academic achievements, and your interest in ACHILLES and the specific research project.  If applying to more than one project, a separate motivation letter for each project is required .

Master’s certificate , or if not yet awarded, proof that the degree will be obtained by the time of recruitment along with your Bachelor’s certificate.

Academic transcripts or grade reports  from your Master’s and/or Bachelor’s programs.

Before applying, please read carefully the details and specific requirements of the available search projects on the ACHILLES website.

Doctoral Candidate (DC) position:

DC1:  Mathematical Modelling of the Immunotherapies in Hematologic Malignancies.  A Master's degree in Mathematics is mandatory for this position.

DC2:  Defining the Mechanistic Impact of PTPN
11 Mutations on Leukemic Transformation and Disease Progression in Juvenile Myelomonocytic Leukemia

DC3:  Investigating Mechanisms of Brain Infiltration and Chemotherapy Resistance in T-cell Acute Lymphoblastic Leukemia

DC4:  Determining the Long-lasting Impact of T-cell Leukemia and Lymphoma on Hematopoietic niches

DC5:  Identifying Rational Approaches to Enhance the Activity of the Anti-cancer Drug Venetoclax

DC6:  Mechanisms of Resistance to MEK Inhibitors in Leukemia and Identification of Targeted Therapeutic Approaches

DC7:  Enhancing CAR-NK Cell Therapies to Target Acute Myeloid Leukemia and Overcome Immune Resistance

DC8:  Prevent Progression of Myelofibrosis to Acute Myeloid Leukemia

DC9:  Characterization of AID-dependent Mutations on Micro

RNA Function

DC10:  AI-driven Proteoform-based Drug Repurposing for Targeted Cancer Therapies

DC11:  RNA Methylation Gain as a Mechanism of Resistance to Therapy in Myelodysplastic Syndromes

DC12:  Optimization and Preclinical Evaluation of Novel SHP2

DC13:  CAR-T cell Double Targeting Strategies to Overcome Tumor Antigen Escape and Microenvironment Inhibition

DC14:  Development of Therapeutic Antibodies for Treating Acute Myeloid Leukemia

DC15:  Novel preclinically-validated GATA3 inhibitor/degrader as a therapy for T-cell Acute Lymphoblastic Leukemia

DC16:  Targeting Metabolic Pathways in Leukemic Stem Cells for AML Treatment

Candidates must not hold a doctoral…